OKYO Pharma Limited (LON:OKYO – Get Free Report) shares dropped 24.3% on Tuesday . The stock traded as low as GBX 1.40 ($0.02) and last traded at GBX 1.40 ($0.02). Approximately 364,142 shares were traded during trading, a decline of 16% from the average daily volume of 431,999 shares. The stock had previously closed at GBX 1.85 ($0.02).
OKYO Pharma Stock Performance
The company has a quick ratio of 2.65, a current ratio of 0.83 and a debt-to-equity ratio of 1.65. The business has a 50 day moving average of GBX 1.40 and a 200 day moving average of GBX 1.40. The company has a market capitalization of £23.24 million, a P/E ratio of -140.00 and a beta of -0.06.
OKYO Pharma Company Profile
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain.
Further Reading
- Five stocks we like better than OKYO Pharma
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Comprehensive PepsiCo Stock Analysis
- Pros And Cons Of Monthly Dividend Stocks
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Short Selling: How to Short a Stock
- Bear Market Funds to Watch This Year
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
